Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

Valdoxan is a novel antidepressant indicated in the treatment of major depressive episodes in adults. The recommended dose of Valdoxan is 1 tablet of 25 mg once daily, taken orally at bedtime. After 2 weeks of treatment, if there is no improvement of symptoms, the dose of Valdoxan may be increased to 50 mg once [...]